Low-Dose Lenalidomide after Non-Myeloablative Allogeneic Hematopoietic Cell Transplant with Bortezomib as GVHD Prophylaxis in High-Risk Multiple Myeloma

Publication date: Available online 8 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jack Khouri, Frederic Reu, Navneet S. Majhail, Aaron Gerds, Deepa Jagadeesh, Robert Dean, Ronald Sobecks, Betty K. Hamilton, Brad Pohlman, Brian T. Hill, Donna Corrigan, Matt Kalaycio, Brian J. Bolwell, Hien D. Liu
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research